Dimethylphosphinylessigsaeureethylester | 17534-98-4

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 英文名称: Dimethylphosphinylessigsaeureethylester
• 英文别名: Dimethyl-ethoxycarbonylmethyl-phosphinoxid；Ethyl 2-dimethylphosphorylacetate
• CAS: 17534-98-4
• 化学式: C₆H₁₃O₃P
• 分子量: 164.141
• InChiKey: JSVTXBMQMKLIQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Dimethylphosphinylessigsaeureethylester 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 2-(dimethylphosphinoyl)acetic acid
  参考文献：
  名称：

  Malevannaya,R.A. et al., Journal of general chemistry of the USSR, 1971, vol. 41, p. 2385 - 2389

  摘要：

  DOI：
• 作为产物：
  描述：

  Brom-chlor-dimethyl-ethoxycarbonylmethyl-phosphin 在 乙醛 作用下， 生成 Dimethylphosphinylessigsaeureethylester
  参考文献：
  名称：

  Gladshtein,B.M.; Zimin,V.M., Journal of general chemistry of the USSR, 1967, vol. 37, p. 1949 - 1952

  摘要：

  DOI：

文献信息

• GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：SK CHEMICALS CO., LTD.

  公开号：US20150166558A1

  公开（公告）日：2015-06-18

  Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

  揭示了一种促性腺激素释放激素受体拮抗剂和包括该拮抗剂的药物组合物，可用于预防或治疗与性激素相关的疾病，如子宫内膜异位症、闭经、月经不调、子宫肌瘤、子宫纤维瘤、多囊卵巢综合征、红斑狼疮、多毛症、性早熟、身材矮小、痤疮、脱发、性腺类固醇依赖性肿瘤、促性腺激素产生垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕症，以及阿尔茨海默病。
• INDOLE DERIVATIVES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150284383A1

  公开（公告）日：2015-10-08

  The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1e , R 1f , A, X, Y, Z, and W 4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了公式I的吲哚衍生物及其药学上可接受的盐和溶剂化合物，其中R1e、R1f、A、X、Y、Z和W4如规范中所述。本发明还提供了利用公式I的化合物及其药学上可接受的盐和溶剂来治疗疼痛。在某些实施例中，本发明的化合物对于治疗对一个或多个钠通道阻滞有响应的疾病是有效的。
• HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20170240512A1

  公开（公告）日：2017-08-24

  The present invention relates to a compound represented by Formula (I): wherein -L- is —C(═X)—, or the like, —Z— is —NR 5 —, or the like, —Z A — is —NR 5A —, or the like, —W— is —C(R 8 R 9 )n-, —W A — is —C(R 3 R 4 )m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R 2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物：其中-L-为—C(═X)—，或类似的，—Z—为—NR5—，或类似的，—ZA—为—NR5A—，或类似的，—W—为—C(R8R9)n-，—WA—为—C(R3R4)m-，B为取代或未取代的芳香环烃基，或类似的，Y为键，或类似的，环C为取代或未取代的芳香杂环，或类似的，R2为氢原子，或类似的，或其药学上可接受的盐，或包括其的药物组成。
• ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE
  申请人：DAIKIN INDUSTRIES, LTD.

  公开号：US20200280096A1

  公开（公告）日：2020-09-03

  An electrolyte solution containing a compound represented by the following formula (1): wherein R 101 and R 102 are the same as or different from each other and are each a hydrogen atom, a fluorine atom, or an alkyl group optionally containing a fluorine atom; and R 103 is an alkyl group or an organic group containing an unsaturated carbon-carbon bond. Also disclosed is an electrochemical device and lithium ion secondary battery including the electrolyte solution, and a module including the electrochemical device or lithium ion secondary battery.

  一种电解质溶液，包含由以下化学式（1）表示的化合物：其中R101和R102彼此相同或不同，分别为氢原子、氟原子或含有氟原子的烷基基团；R103为烷基基团或含有不饱和碳-碳键的有机基团。还公开了包括该电解质溶液的电化学器件和锂离子二次电池，以及包括电化学器件或锂离子二次电池的模块。
• NON-AQUEOUS LIQUID ELECTROLYTE, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHORUS COMPOUND USED THEREIN
  申请人：UBE INDUSTRIES, LTD.

  公开号：US20170275311A1

  公开（公告）日：2017-09-28

  The present invention is concerned with a nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent, the nonaqueous electrolytic solution containing a compound represented by the following general formula (X), in which a polar group (X) is bound to a phosphorus atom (P), and capable of improving electrochemical characteristics in a broad temperature range; an energy storage device using the same; and a novel compound. In the formula, R 10 and R 20 are each independently an organic group selected from the group consisting of an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 3 to 6 carbon atoms, and an aryl group having 6 to 12 carbon atoms, or a lithium atom; and X is a polar group (i) containing a —C(═O) group, a —P(═O) group, or an —S(═O) 2 group, a polar group (ii) containing a —CN group or an alkyl group having 1 to 6 carbon atoms, in which a part of hydrogen atoms is substituted with a fluorine atom, or a 4- to 7-membered ring polar group (iii) containing a —C(═O)—O— group or a —C(═O)—N— group, provided that when X is a 4- to 7-membered ring polar group (iii) containing a —C(═O)—N— group, at least one of R 10 and R 20 is a lithium atom.

  本发明涉及一种非水电解质溶液，其中电解质盐溶解在非水溶剂中，该非水电解质溶液含有以下通式（X）所代表的化合物，其中极性基（X）与磷原子（P）结合，并能够改善广泛温度范围内的电化学特性；使用该非水电解质溶液的储能装置；以及一种新化合物。在该公式中，R10和R20分别独立地是从包括具有1至8个碳原子的烷基基团、具有2至6个碳原子的烯基基团、具有3至6个碳原子的炔基基团和具有6至12个碳原子的芳基基团或锂原子中选择的有机基团；X是一个极性基（i），其中包含一个—C(═O)基团、一个—P(═O)基团或一个—S(═O)2基团，一个极性基（ii），其中包含一个—CN基团或一个具有1至6个碳原子的烷基基团，其中部分氢原子被氟原子取代，或一个4至7环极性基（iii），其中包含一个—C(═O)—O—基团或一个—C(═O)—N—基团，但当X是一个包含一个—C(═O)—N—基团的4至7环极性基（iii）时，至少一个R10和R20是锂原子。